Scarica l'app Stockscreener
9.27
1.49%
-0.14
Dopo l'orario di chiusura:
9.25
-0.02
-0.22%
Oculis Holding Ag Borsa (OCS) Ultime notizie
(OCS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - Zacks Investment Research
H.C. Wainwright raises Oculis stock price target to $39 on DED trial progress - Investing.com Nigeria
Oculis Holding AG (OCS) Stock Analysis: Unveiling a Potential 254.75% Upside in the Biotech Space - DirectorsTalk Interviews
Oculis Holding AG: Navigating Through Major Trial Setback (NASDAQ:OCS) - Seeking Alpha
A board member bought Oculis shares - Stock Titan
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Why (OCS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Oculis at H.C. Wainwright conference: biomarker bet and neurology push - Investing.com
OCS: Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding - TradingView
Oculis at H.C. Wainwright conference: biomarker bet and neurology push By Investing.com - Investing.com Canada
Oculis Holding AG Ordinary shares (NASDAQ: OCS) Share Price, OCS Stock News, OCS Share Price & Updates - Kalkine
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - qz.com
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis doses first patient in phase 3 privosegtor trial for ON - Glance by Eyes On Eyecare
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.79 as Consolidation ContinuesVolatility Smile - dars.gov.et
Oculis Holding - The Pharma Letter
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com
There Is No Approved Specific Treatment for Acute Optic Neuritis. Oculis Is Testing One. - stocktitan.net
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - The Manila Times
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Earnings Reading: EPS Lands Above Forecast in the Latest Session; Post-Report: The Share Price Adds 2.88% at the CloseReturn On Capital - dars.gov.et
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis (OCS) Latest Earnings Reading: EPS Exceeds Its Estimate in the Latest Reading; Share Response: Shares Move 0.38% Up at the CloseRevenue Beat Analysis - dars.gov.et
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat
Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci
Oculis Holding AG (OCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights - Stock Titan
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - The Manila Times
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ... - pmg-ky3.com
Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares - Bitget
Oculis acquires full rights to Privosegtor, boo... - Pluang
Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase - Quiver Quantitative
Oculis Signs Asset Purchase Agreement with Accure - GlobeNewswire
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation ContinuesStandard Deviation - siam.in
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results - MarketBeat
Oculis Holding earnings beat by CHF0.23, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell - MarketBeat
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):